CORT insider sale: 20,000 shares reported

Corcept Therapeutics (CORT) notice under Rule 144 reports a sale of 20,000 common shares tied to a stock option exercise on 04/07/2026 for $817,000 via Stifel Nicolaus & Company.

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) notice under Rule 144 reports a sale of 20,000 common shares tied to a stock option exercise on 04/07/2026 for $817,000 via Stifel Nicolaus & Company. The filing lists prior sales by William Guyer in 02/03/2026 (20,000 shares, $817,333), 03/04/2026 (8,233 shares, $296,346), and 03/20/2026 (11,767 shares, $423,707).

Insights

Securities Compliance Analyst

Rule 144 sale notice records option exercise followed by resale reporting.

The filing documents a stock option exercise and subsequent sale of 20,000 common shares on 04/07/2026, with proceeds shown as $817,000. It also itemizes three prior sales by the same registrant in early 2026.

These entries serve as a transfer/resale disclosure under Rule 144; cash‑flow recipient is the seller as disclosed via the broker entry. Timing and broader ownership context are not provided in the excerpt.

Key Figures

Shares sold (04/07/2026): 20,000 shares Proceeds (04/07/2026): $817,000 Prior sale (02/03/2026): 20,000 shares +2 more

5 metrics

Shares sold (04/07/2026) 20,000 shares Stock option exercise reported 04/07/2026

Proceeds (04/07/2026) $817,000 Cash amount shown for 20,000 shares on 04/07/2026

Prior sale (02/03/2026) 20,000 shares Sale by William Guyer on 02/03/2026 for $817,333

Prior proceeds (03/04/2026) $296,346 Proceeds for 8,233 shares sold 03/04/2026

Prior proceeds (03/20/2026) $423,707 Proceeds for 11,767 shares sold 03/20/2026

Key Terms

Rule 144, Stock Option Exercise, Stifel Nicolaus & Company

3 terms

Rule 144 regulatory

"Filer Information | 144: Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 04/07/2026 | Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Stifel Nicolaus & Company market

"Stifel Nicolaus & Company Inc. 501 N. Broadway"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Corcept Therapeutics (CORT) Form 144 report?

It reported a resale of 20,000 common shares tied to a stock option exercise on 04/07/2026 for $817,000. The notice also lists three prior sales by William Guyer in February and March 2026 with specific share counts and proceeds.

Who sold the shares reported in the CORT Form 144?

The filing lists William Guyer as the seller for multiple transactions. The current entry shows sale via Stifel Nicolaus & Company and prior sales on 02/03/2026, 03/04/2026, and 03/20/2026 with amounts shown in dollars.

How many shares and proceeds are shown in the April 7, 2026 CORT entry?

The April 7, 2026 entry shows 20,000 shares associated with a stock option exercise and a cash amount of $817,000 reported through the broker Stifel Nicolaus & Company on NASDAQ for Corcept Therapeutics common stock.

Does the Form 144 disclose when prior sales occurred for this filer?

Yes. The excerpt lists prior sale dates and amounts: 02/03/2026 (20,000 shares, $817,333), 03/04/2026 (8,233 shares, $296,346), and 03/20/2026 (11,767 shares, $423,707).

Was the April 7 transaction an exercise or open‑market sale in the CORT filing?

The April 7 entry is recorded as a stock option exercise with the securities to be sold noted and the sale method as Cash through the broker listing. The filing labels the transaction as "Stock Option Exercise."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 12:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001879013
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	Guyer William
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N. Broadway St. Louis MO 63102	20000	817000.00	106370000	04/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/07/2026	Stock Option Exercise	Corcept Therapeutics Inc.			20000	04/07/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	02/03/2026	20000	817333.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	03/04/2026	8233	296346.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	03/20/2026	11767	423707.00

144: Remarks and Signature

Remarks
Date of Notice	04/07/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/27/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Toni Dobel, as a duly authorized representative of STIFEL, as attorney-in-fact for William Guyer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)